Annual and Interim Reports
Annual General Meeting
Annual Report 2016
Conflict Minerals Disclosure
Quarterly Results and Presentations
WHO WE ARE
How We Operate
Our R&D Strategy
RESEARCH AND EDUCATIONAL GRANTS
Science & Innovation
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
US Internship Program
Work Life Balance
Please download the file below for more information:
Click here for the PDF version of this press release.
Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
MYDAYIS™ (mixed salts of a single-entity amphetamine product), Shire’s New Once-Daily ADHD Treatment, Now Available in the U.S.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.